Search Results

Artificial Intelligence for Drug Discovery Call for GPCR Papers GPCRs: Signal Transduction.

Listing Rule 5635(c)(4) arcoscreen is one of the 13 biotech companies to discover in western in 2023 Call

announce that we've been working tirelessly to bring you a simple, beautiful, and insightful collection of all This is your last call before the curtain drops: Classified GPCR News is going VIP-only next year! That's right, all the tidbits below will be for Premium Members ' eyes only.

Call for GPCR Papers GPCRs: Signal Transduction. Ends tomorrow - March 31st, 2023.

You can find all the necessary information on the Logo Contest page. to Vertex for $48 million Merck KGgA collaborates with Exscientia plc in deal worth up to $674M 2023 Half-Year

All information is available on the Logo Contest page. Program Receives €4 Million Grant Confo Therapeutics Appoints Stephen Dowd As Chief Business Officer Call

) Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Call

Targeted and Immuno-oncology Sosei Heptares Adds World-leading Expertise to its Scientific Advisory Board Call

Gregory Tall and team's study on GPR114/ADGRG5, activated by tethered-peptide-agonist, a cleaved adhesion substance use disorders Industry News Crinetics’ Once-Daily Oral Paltusotine Achieved The Primary And All Stephen Dowd As Chief Business Officer Septerna Announces Novel GPCR-targeted Program Acquired by Vertex Call

With just one week left, becoming a premium member is all it takes to benefit from this discount! Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Call

Global Healthcare Conference CEO Raymond Stevens to Speak at STAT Future Summit on Obesity Therapeutics Call

By increasing sensitivity, so-called “silent” antagonists reveal themselves as weak agonists.

When Two Mechanisms Look the Same Some of the most difficult calls in pharmacology happen when two different

However, over half of non-sensory GPCRs do not have drugs available in the clinic, opening the door to Our portfolio also includes all kinds of dyes, such as pharmacophores conjugated to near-infrared fluorophores Another issue, that is present in all probes but can sometimes be stronger in fluorescent ligands, is Soave M, Briddon SJ, Hill SJ, Stoddart LA.

Heptares and Neurocrine Biosciences won Top Out-Licensing Deal on the 8th annual Japan Deal of the Year Call

We're sending you all the good vibes and a sprinkle of birthday magic for an epic celebration! Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2 Call

Biosciences, INC as a Preferred Supplier at Prendio Crinetics Pharmaceuticals announces executive departure Call

opportunity to generate proprietary chemo-informatics for GPCR drug discovery - Design Pharmaceuticals Call

The course covers basic pharmacology in four weekly segments and is open to all with a free site membership with advanced gastroenteropancreatic neuroendocrine tumors Neurocrine Biosciences Announces Conference Call

Greetings to all! Terry Kenakin will conduct two back-to-back courses this fall.

Call for GPCR Papers GPCRs: Signal Transduction Advances in Computational and Chemical Methods to study

Enzyme inhibition isn’t one-size-fits-all. enzyme class is more important—or more unpredictable—than cytochrome P450s .CYP3A4 alone handles over half of all marketed drugs. scientists can name “competitive” inhibition, but in this lesson, Terry makes sure everyone understands  all When Inhibition Becomes Activation Not all enzyme interactions are suppressive.

We aim to make education accessible to all! behavior in important human cell regulator, opening up a new drug target for cancer, other diseases Call

and Pharmacology Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call

development DeepCure team is excited to welcome Justin Potnick, to our Medicinal Chemistry group Call

Chinese hamster ovary-K1 cells and its use in the G-protein-coupled receptor assays Predicting the Hallucinogenic

phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study Call

We’re committed to making education accessible to all! Adiso Announces Groundbreaking Research Highlighting ADS024 a Novel Oral Agent for Neuroinflammation Call

Why Traditional Radioligand Methods Fall Short for Modern Screening Needs Radioligand binding assays

Discovery Upstream Bio Announces the Appointment of Marcella Ruddy, M.D., to the Board of Directors Call